Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

Equity Analysts at Barclays Cut Regeneron Pharma (NASDAQ:REGN) from Equal Weight to Underweight Rating Having $395.0 Target

Barclays Capital Analyst Rating Change Regeneron Pharma NASDAQ:REGN

Regeneron Pharma (NASDAQ:REGN) Change of Rating

Barclays has decreased Regeneron Pharma (NASDAQ:REGN) stock to Underweight in a report issued to investors and clients on 20 October, and has set a 12-month TP at $395.0. REGN’s old rating was Equal Weight.

This rating downgrade is probably noticed by stock traders, as NASDAQ:REGN is currently trading -1.75% lower at $433.21 as of 4:03 AM New York time. Regeneron Pharma’s stock is 0% over the past 200 days. It has underperformed the S&P 500 Index, which has increased 6.00% over the same time period.

According to data compiled by Thomson Reuters, Regeneron Pharma (NASDAQ:REGN)’s stock is covered by 21 equity analysts across the Street, with 1 analysts giving it a Sell rating, 14 a Buy rating, while 11 consider it a Hold. The 12-month consensus target price for the stock is $475.76, which reflects an upside potential of 9.82% over the current price.

Institutional Ownership

Lagoda Investment Management L.P. had the biggest stake with ownership of 73,131 shares as of q2 2015 for 8.84% of the US long stock exposure. Polen Capital Management Llc is another very bullish investment professional who is having 811,301 shares of Regeneron Pharma or 3.89% of their US long stock exposure. Moreover, Ray Gerald L & Associates Ltd have 3.5% of their US long stock exposure invested in the company for 58,084 shares. The Illinois-based fund Premier Asset Managment Llc revealed it had acquired a stake worth about 3.48% of the investment professional’s stock portfolio in Regeneron Pharma. The Switzerland-based fund Bb Biotech Ag is also positive about the stock, possessing 34,840 shares or 3.46% of their US long stock exposure.

Regeneron Pharma (NASDAQ:REGN) Profile

Regeneron Pharmaceuticals IncRegeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company’s marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.

Regeneron Pharma (NASDAQ:REGN) traded down -1.75% on 20 October, hitting $433.21. A total of 382,567 shares of the company’s stock traded hands. This is down from average of 799,072 shares. Regeneron Pharma has a 52 week low of $325.35 and a 52 week high of $543.55. The company has a market cap of $46.42B and a P/E ratio of 43.48.

Get the latest Regeneron Pharma (NASDAQ:REGN) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

The post Equity Analysts at Barclays Cut Regeneron Pharma (NASDAQ:REGN) from Equal Weight to Underweight Rating Having $395.0 Target appeared first on Octafinance.



This post first appeared on Octafinance – Financial News, Reports And Intell, please read the originial post: here

Share the post

Equity Analysts at Barclays Cut Regeneron Pharma (NASDAQ:REGN) from Equal Weight to Underweight Rating Having $395.0 Target

×

Subscribe to Octafinance – Financial News, Reports And Intell

Get updates delivered right to your inbox!

Thank you for your subscription

×